Key Drivers
- High gross margins
- Negative FCF/earnings
- Very high leverage
AIAI Summary
Tempus's pivot from a speculative AI platform to a hybrid diagnostics + data‑licensing company with accelerating diagnostics growth and >$1.1B TCV materially de‑risks top‑line optionality—but the investment hinges on rapid conversion of multiyear bookings into recognized revenue and cash, plus containment of reimbursement/ASP pressure and dilution risk, making near‑term cash‑flow and adjusted‑EBITDA execution the decisive catalysts for upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Negative FCF/earnings
- •Very high leverage
TEM has strong gross margins and solid short‑term liquidity but is loss‑making with negative operating and free cash flow and high leverage, relying on external financing to sustain operations.
Price Behavior
Key Price Behavior Insights:
- •Short‑term downtrend
- •RSI near oversold
- •Defined support/resistance
Stock is in a short‑term downtrend (closed $46.96 below its last month SMA ~$52.6) with weak RSI (~35) near oversold, clear support at $46.96/$49–$51 and resistance at ~$52.6 and $58–$60 after a ~33% drop from the January peak.
Elevated volatility with ~33% drop from $70.33 in mid‑January showing strong selling pressure
Sentiment & News
Key News Insights:
- •Revenue surge
- •Strategic partnership
- •Profitability risk
Tempus reported blockbuster revenue growth and a Merck collaboration but posted a loss and volatile shares as investors balance rapid diagnostics/AI momentum against profitability concerns.
The developments boost long-term growth narrative but near-term stock risk remains elevated until consistent profitability is demonstrated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings